NCT04514653 - RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE) | Biotech Hunter

Enrollment

115

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

October 21, 2025

Study Completion Date

August 1, 2026

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

BIOLOGICAL

Ranibizumab

Ranibizumab (anti-VEGF agent)

GENETIC

RGX-314 Dose 1

AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)

GENETIC

RGX-314 Dose 2

AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)

GENETIC

RGX-314 Dose 3

AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)

DRUG

Local Steroid

Local steroid

DRUG

Topical Steroid

Topical steroid

Trial Locations (15)

19107

RECRUITING

Philadelphia Location, Philadelphia

21287

RECRUITING

Baltimore Location, Baltimore

30909

RECRUITING

Augusta Location, Augusta

37203

ACTIVE_NOT_RECRUITING

Nashville Location, Nashville

38138

ACTIVE_NOT_RECRUITING

Germantown Location, Germantown

77384

ACTIVE_NOT_RECRUITING

Woodlands Location, The Woodlands

85014

RECRUITING

Phoenix Location, Phoenix

87109

RECRUITING

Albuquerque Location, Albuquerque

89502

RECRUITING

Reno Location, Reno

90211

RECRUITING

Beverly Hills Location, Beverly Hills

92064

RECRUITING

Poway Location, Poway

93103

ACTIVE_NOT_RECRUITING

Santa Barbara Location, Santa Barbara

93309

ACTIVE_NOT_RECRUITING

Bakersfield Location, Bakersfield

94040

RECRUITING

Mountain View Location, Mountain View

02114

RECRUITING

Boston Location, Boston